glp 1 and propranolol Cardiovascular effects of Glucagon-like peptide (GLP-1) receptor agonists | Cardiovascular Diabetology One of my Blood Sugar

Hasin DS, Kerridge BT, Saha TD, Huang B, Pickering R, Smith SM, et al

Retatrutide could become Eli Lilly's next major drug after Mounjaro and Zepbound

They help raise insulin and suppress the hormone glucagon, which plays a role in both appetite and Type 2 diabetes

Access and supply Who gets these drugs depends on your insurance

In a recent meta-analysis of 12 observational studies of patients with T2DM treated with either SGLT2 inhibitors or GLP-1RAs, the GLP-1RA group exhibited a significantly lower relative risk of lower limb amputation vs the SGLT2 inhibitor cohort (3.54 vs 4.72 events per 1000 patient-years).37 Furthermore, in the CANVAS program involving 10,142 patients with T2DM at high cardiovascular risk, canagliflozin was found to be associated with a 1.97-fold increased risk of lower-limb amputations

GLP-1 Receptor agonists and kidney protection